Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-05. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Reincarnation is a paramount tenet in the Druze faith. There is an eternal duality of the body and the soul and it is impossible for the soul to exist without the body. Therefore, reincarnations occur instantly at one's death. While in the Hindu and Buddhist belief system a soul can be transmitted to any living creature, in the Druze belief system this is not possible and a human soul will only transfer to a human body. Furthermore, souls cannot be divided into different or separate parts and the number of souls existing is finite. A male Druze can be reincarnated only as another male Druze and a female Druze only as another female Druze. A Druze cannot be reincarnated in the body of a non-Druze. The cycle of rebirth is continuous and the only way to escape is through a complete soul purification. When this occurs, the soul is united with the Cosmic Mind and achieves the ultimate goal. In the major Christian denominations, the concept of reincarnation is not present and it is nowhere explicitly referred to in the Bible. However, the impossibility of a second earthly death is stated by 1 Peter 3:18–20, where it affirms that the messiah, Jesus of Nazareth, died once forever for the sins of all the human kind. Matthew 14:1–2 mentions that king Herod Antipas took Jesus to be a risen John the Baptist, when introducing the story of John's execution at Herod's orders. Some Christian theologians interpret certain Biblical passages as referring to reincarnation.
The Hippocratic Oath for physicians, attributed to fifth century BC Greece, refers to the existence of "deadly drugs", and ancient Greek physicians imported drugs from Egypt and elsewhere. The pharmacopoeia De materia medica, written between 50 and 70 CE by the Greek physician Pedanius Dioscorides, was widely read for more than 1,500 years.
=== Modern research === In August 2018, scientists announced the transformation of gaseous deuterium into a liquid metallic form. This may help researchers better understand gas giant planets, such as Jupiter, Saturn and some exoplanets, since such planets are thought to contain a lot of liquid metallic hydrogen, which may be responsible for their observed powerful magnetic fields.
Sources: en.wikipedia.org
Biotextiles are specialized materials engineered from natural or synthetic fibers. These textiles are designed to interact with biological systems, offering properties such as biocompatibility, porosity, and mechanical strength or are designed to be environmentally friendly for typical household applications. There are several uses for biotextiles since they are a broad category. The most common uses are for medical or household use. However, this term may also refer to textiles constructed from biological waste products. These biotextiles are not typically used for industrial purposes. The term "biotextiles" derives from the combination of "bio," referring to biology or living organisms, and "textiles," indicating woven or fibrous materials. It encompasses the interdisciplinary field of biomedical textiles, which focuses on the design, fabrication, and application of textile materials in healthcare and biomedical engineering. Biotextiles made from mycelium, vegetable biomass, bacterial cellulose, and recombinant protein based fibers are used as an alternative to synthetic textiles to prevent and reduce the high greenhouse gas emissions, water pollution, and landfill waste from the textile industry. Biotextiles are also used within healthcare and the biomedical engineering field as implantable devices such as surgical sutures, hernia repair fabrics, arterial grafts, artificial skin and parts of artificial hearts.
=== Adverse effects === The most common adverse effects of medicinal nicotinic acid (500–3000 mg) are flushing (e.g., warmth, redness, itching or tingling) of the face, neck and chest, headache, abdominal pain, diarrhea, dyspepsia, nausea, vomiting, rhinitis, pruritus and rash. These can be minimized by initiating therapy at low dosages, increasing dosage gradually, and avoiding administration on an empty stomach. The acute adverse effects of high-dose nicotinic acid therapy (1–3 grams per day) – which is commonly used in the treatment of hyperlipidemias – can further include hypotension, fatigue, glucose intolerance and insulin resistance, heartburn, blurred or impaired vision, and macular edema. With long-term use, the adverse effects of high-dose nicotinic acid therapy (750 mg per day) also include liver failure (associated with fatigue, nausea, and loss of appetite), hepatitis, and acute liver failure; these hepatotoxic effects of nicotinic acid occur more often when extended-release dosage forms are used. The long-term use of nicotinic acid at greater than or equal to 2 grams per day also significantly increases the risk of cerebral hemorrhage, ischemic stroke, gastrointestinal ulceration and bleeding, diabetes, dyspepsia, and diarrhea.
=== Essays === FEMEN, Manifeste FEMEN, éditions Utopia, 2014 ISBN 978-2919160174. Héroïnes de la rue, Manifeste pour un féminisme de combat, éditions Michel Lafon, 2020 ISBN 978-2749943961. avec Dora Moutot, Transmania, Magnus, 2024.
24395Am + 2210Ne → 265−x105 + x n (x = 4, 5) After observing the alpha decays of element 105, the researchers aimed to observe spontaneous fission (SF) of the element and study the resulting fission fragments. They published a paper in February 1970, reporting multiple examples of two such activities, with half-lives of 14 ms and 2.2±0.5 s. They assigned the former activity to 242mfAm and ascribed the latter activity to an isotope of element 105. They suggested that it was unlikely that this activity could come from a transfer reaction instead of element 105, because the yield ratio for this reaction was significantly lower than that of the 242mfAm-producing transfer reaction, in accordance with theoretical predictions. To establish that this activity was not from a (22Ne,xn) reaction, the researchers bombarded a 243Am target with 18O ions; reactions producing 256103 and 257103 showed very little SF activity (matching the established data), and the reaction producing heavier 258103 and 259103 produced no SF activity at all, in line with theoretical data. The researchers concluded that the activities observed came from SF of element 105. In April 1970, a team at Lawrence Berkeley Laboratory (LBL), in Berkeley, California, United States, claimed to have synthesized element 105 by bombarding californium-249 with nitrogen-15 ions, with an alpha activity of 9.1 MeV. To ensure this activity was not from a different reaction, the team attempted other reactions: bombarding 249Cf with 14N, Pb with 15N, and Hg with 15N. They stated no such activity was found in those reactions.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.